Urticaria: A comprehensive review : Treatment of chronic urticaria, special populations, and disease outcomes - 19/09/18
![](/templates/common/images/mail.png)
Abstract |
Second-generation antihistamines are considered first-line agents in the treatment of chronic urticaria because of their safety and efficacy profile. Some patients require higher doses of H1 antihistamines alone or in combination with other classes of medications, including H2 antihistamines, leukotriene receptor antagonists, or first-generation H1 antihistamines. One major therapeutic advance has been omalizumab, a humanized monoclonal anti–immunoglobulin E that was recently approved by the US Food and Drug Administration for the treatment of chronic urticaria that is unresponsive to H1 antagonists. In addition, the second article in this continuing medical education series outlines several evidence-based alternative treatments for urticaria and the differences in recommendations between 2 major consensus groups (the European Academy of Allergy and Clinical Immunology/World Allergy Organization and the American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force).
Le texte complet de cet article est disponible en PDF.Key words : acute, antihistamines, children, chronic, corticosteroids, elderly, leukotriene receptor antagonists, management, omalizumab, quality of life, urticaria
Abbreviations used : ASST, AU, BB-UVB, CSU, CsA, CU, DPU, fgAH, LTRA, MMF, NB-UVB, PUVA, RCT, sgAH, UAS
Plan
Date of release: October 2018 |
|
Expiration date: October 2021 |
|
Funding sources: None |
|
Conflicts of interest: None disclosed. |
Vol 79 - N° 4
P. 617-633 - octobre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?